271 Can Plasma Exchange Slow Aging? What the Circulate Trial Reveals with Dr. Brad Younggren

What if aging is not only driven by what happens inside our cells, but also by factors circulating in our blood? In this thought-provoking episode, Dr. Gillian Lockitch talks with Brad Younggren to explore the emerging science behind therapeutic plasma exchange and its potential to influence inflammation, biological aging, and chronic disease. Drawing on human clinical trial data, including the Circulate Trial, he explains how removing pro-aging factors from plasma may impact biomarkers, biological age, and overall healthspan. This conversation offers a fascinating glimpse into the future of longevity medicine while reinforcing the importance of foundational lifestyle strategies for aging youthfully. Dr. Brad Younggren is the CEO and co-founder of Circulate Health, a company focused on advancing human healthspan through innovative therapies. He is a board-certified emergency physician and former U.S. Army combat physician, where he was awarded the Bronze Star and Combat Medical Badge. Dr. Younggren has held multiple leadership roles at the forefront of healthcare innovation, including President and Chief Medical Officer at 98.6, where he helped develop AI-powered primary care solutions. His career spans digital health, medical devices, and global healthcare delivery. Today, he leads research into therapeutic plasma exchange and its potential role in longevity science and chronic disease. Episode Timeline: 00:00 – Welcome and introduction 02:30 – Aging beyond the cell: circulating factors in the bloodstream and their role in inflammation and disease 05:00 – Dr. Younggren's journey from emergency medicine to healthcare innovation and longevity science 09:00 – The evolution of digital health and smartphone-based diagnostics 12:00 – What is therapeutic plasma exchange and how it has been used in medicine for decades 15:45 – The Circulate Trial explained: study design, treatment groups, and control methodology 18:30 – Measuring outcomes: biomarkers, cognitive testing, grip strength, and biological clocks 21:00 – Key findings: biological age reduction and changes in proteomic markers 24:30 – Translating complex science into practical biomarkers patients can track 26:30 – Applications beyond longevity: chronic disease, Alzheimer's research, and long COVID 30:30 – Microplastics and plasma exchange: emerging research and early findings 33:00 – Evaluating longevity therapies: why human data matters 35:30 – Foundational health habits versus advanced interventions 36:50 – Wrap-up and key takeaways Connect with Dr. Brad Younggren Circulate Health: <a class="HyperlinkV2 SCXO106336817 BCX0" href= "https: